ORGO
HEALTHCAREOrganogenesis Holdings Inc - Class A
$2.56-0.03 (-1.16%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ORGO Today?
No stock-specific AI insight has been generated for ORGO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.21$7.08
$2.56
Fundamentals
Market Cap$329M
P/E Ratio17.1
EPS$0.15
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding128.7M
ORGO News
21 articles- Organogenesis (ORGO) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- Organogenesis Holdings Inc. Q1 2026 Earnings Call SummaryMoby·May 8, 2026
- Organogenesis Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Organogenesis Holdings Inc. Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®Yahoo Finance·Apr 28, 2026
- Tissue Engineering Market to Grow at 12.95% CAGR Reaching USD 27.59 Billion by 2031, Driven by Advances in Regenerative Medicine and Biomaterials, Says Mordor IntelligenceGlobeNewswire Inc.·Apr 24, 2026
- Undiscovered Gems In The US Market Featuring 3 Promising StocksYahoo Finance·Apr 15, 2026
- 3 Penny Stocks With Market Caps Under $400M To ConsiderYahoo Finance·Apr 13, 2026
- Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AMGlobeNewswire Inc.·Apr 6, 2026
- Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis PainYahoo Finance·Apr 6, 2026
- Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 6, 2026
- Organogenesis Holdings Inc. Q4 2025 Earnings Call SummaryMoby·Feb 27, 2026
- Organogenesis Q4 Earnings Call HighlightsMarketbeat·Feb 27, 2026
- Organogenesis Holdings Inc (ORGO) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid ...Yahoo Finance·Feb 27, 2026
- Organogenesis (ORGO) Q4 2025 Earnings TranscriptMotley Fool·Feb 26, 2026
- Organogenesis: Q4 Earnings SnapshotYahoo Finance·Feb 26, 2026
- Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record RevenueYahoo Finance·Feb 26, 2026
- Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026Yahoo Finance·Feb 19, 2026
- Undervalued Opportunities: Penny Stocks To Watch In January 2026Yahoo Finance·Jan 26, 2026
- Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Deliver On Growth Plans?Yahoo Finance·Jan 25, 2026
- Organogenesis Announces Initiation of Biologics License Application for ReNu®Yahoo Finance·Dec 23, 2025
All 21 articles loaded
Price Data
Open$0.00
Previous Close$2.59
Day High$0.00
Day Low$0.00
52 Week High$7.08
52 Week Low$2.21
52-Week Range
$2.21$7.08
$2.56
Fundamentals
Market Cap$329M
P/E Ratio17.1
EPS$0.15
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding128.7M
About Organogenesis Holdings Inc - Class A
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—